Article

Brachytherapy's use in prostate Ca is on the rise

Author(s):

Mac Overmyer

Winston-Salem, NC--Well over one-third of men with localized prostatecancer are opting for brachytherapy as their primary treatment, accordingto a recently published study. Past and current data indicate the proportionof prostate cancer patients choosing brachytherapy has grown from 1.4% in1992 to 3.0% in 1995 to 36% in 1999-the latest year for which comprehensivedata are available.

Related Videos
Mohamad Baker Berjaoui, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Justin Dubin, MD, answers a question during a video interview
Related Content
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
December 5th 2024

ADVANCED-2 data demonstrate safety, efficacy of TARA-002 in NMIBC

Benjamin P. Saylor
At month 6, the overall high-grade complete response rate was 72% (13 of 18
Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
Human kidney cross section on scientific background | Image Credit: © Crystal light - stock.adobe.com
December 5th 2024

Investigators characterize safety profile of belzutifan in advanced RCC

Benjamin P. Saylor
Anemia was the most frequently observed any-cause AE and was seen in 485 (84.2%) patients.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
December 5th 2024

Study reveals real-world data of PFS, OS with olaparib for mCRPC

Benjamin P. Saylor
Overall median time from first documented biomarker test date to index date was 5.5 months.
The potential of HER2 targeting in prostate cancer: A case study with trastuzumab deruxtecan
December 4th 2024

The potential of HER2 targeting in prostate cancer: A case study with trastuzumab deruxtecan

Maneesh R. Jain, MD
"That pan-tumor approval and this patient case really highlight that in prostate cancer, we should be checking HER2 by immunohistochemistry," says Maneesh R. Jain, MD.
© 2024 MJH Life Sciences

All rights reserved.